Guardant Health Inc (GH) concluded trading on Thursday at a closing price of $49.94, with 3.24 million shares of worth about $161.84 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 37.61% during that period and on January 30, 2025 the price saw a gain of about 4.81%. Currently the company’s common shares owned by public are about 123.16M shares, out of which, 117.73M shares are available for trading.
Stock saw a price change of 2.76% in past 5 days and over the past one month there was a price change of 64.06%. Year-to-date (YTD), GH shares are showing a performance of 63.47% which increased to 116.19% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $15.81 but also hit the highest price of $49.86 during that period. The average intraday trading volume for Guardant Health Inc shares is 2.10 million. The stock is currently trading 23.40% above its 20-day simple moving average (SMA20), while that difference is up 37.64% for SMA50 and it goes to 76.40% higher than SMA200.
Guardant Health Inc (NASDAQ: GH) currently have 123.16M outstanding shares and institutions hold larger chunk of about 104.13% of that.
The stock has a current market capitalization of $6.17B and its 3Y-monthly beta is at 1.33. It has posted earnings per share of -$4.24 in the same period. It has Quick Ratio of 5.85. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GH, volatility over the week remained 4.24% while standing at 6.38% over the month.
Stock’s fiscal year EPS is expected to rise by 20.26% while it is estimated to increase by 15.08% in next year. EPS is likely to grow at an annualized rate of 16.87% for next 5-years, compared to annual growth of -8.88% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Barclays on January 23, 2025 offering an Overweight rating for the stock and assigned a target price of $60 to it. Coverage by Guggenheim stated Guardant Health Inc (GH) stock as a Buy in their note to investors on June 28, 2024, suggesting a price target of $36 for the stock. On June 03, 2024, Jefferies Resumed their recommendations, while on April 24, 2024, Craig Hallum Resumed their ratings for the stock with a price target of $28. Stock get a Neutral rating from Guggenheim on December 14, 2023.
